Cancer blood-testing company Guardant Health filed for an initial public offering on Thursday, with plans to list on Nasdaq under the ticker symbol "GH." The company said it is aiming to raise $100 million, although that number is likely a placeholder until it sets terms. JP Morgan and BofA Merrill Lynch are lead underwriters on the deal with Cowen, Leerink Partners and William Blair acting as co-managers. "We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets and advanced analytics," the company said in its prospectus.
Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.